AIMS: Sudden cardiac death (SCD) is the most common mode of death in paediatric hypertrophic cardiomyopathy (HCM). This study describes the implant and programming strategies with clinical outcomes following implantable cardioverter-defibrillator (ICD) insertion in a well-characterized national paediatric HCM cohort. METHODS AND RESULTS: Data from 90 patients undergoing ICD insertion at a median age 13 (±3.5) for primary (n = 67, 74%) or secondary prevention (n = 23, 26%) were collected from a retrospective, longitudinal multi-centre cohort of children (<16 years) with HCM from the UK. Seventy-six (84%) had an endovascular system [14 (18%) dual coil], 3 (3%) epicardial, and 11 (12%) subcutaneous system. Defibrillation threshold (DFT) testing was performed at implant in 68 (76%). Inadequate DFT in four led to implant adjustment in three patients. Over a median follow-up of 54 months (interquartile range 28-111), 25 (28%) patients had 53 appropriate therapies [ICD shock n = 45, anti-tachycardia pacing (ATP) n = 8], incidence rate 4.7 per 100 patient years (95% CI 2.9-7.6). Eight inappropriate therapies occurred in 7 (8%) patients (ICD shock n = 4, ATP n = 4), incidence rate 1.1/100 patient years (95% CI 0.4-2.5). Three patients (3%) died following arrhythmic events, despite a functioning device. Other device complications were seen in 28 patients (31%), including lead-related complications (n = 15) and infection (n = 10). No clinical, device, or programming characteristics predicted time to inappropriate therapy or lead complication. CONCLUSION: In a large national cohort of paediatric HCM patients with an ICD, device and programming strategies varied widely. No particular strategy was associated with inappropriate therapies, missed/delayed therapies, or lead complications. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Sudden cardiac death (SCD) is the most common mode of death in paediatric hypertrophic cardiomyopathy (HCM). This study describes the implant and programming strategies with clinical outcomes following implantable cardioverter-defibrillator (ICD) insertion in a well-characterized national paediatric HCM cohort. METHODS AND RESULTS: Data from 90 patients undergoing ICD insertion at a median age 13 (±3.5) for primary (n = 67, 74%) or secondary prevention (n = 23, 26%) were collected from a retrospective, longitudinal multi-centre cohort of children (<16 years) with HCM from the UK. Seventy-six (84%) had an endovascular system [14 (18%) dual coil], 3 (3%) epicardial, and 11 (12%) subcutaneous system. Defibrillation threshold (DFT) testing was performed at implant in 68 (76%). Inadequate DFT in four led to implant adjustment in three patients. Over a median follow-up of 54 months (interquartile range 28-111), 25 (28%) patients had 53 appropriate therapies [ICD shock n = 45, anti-tachycardia pacing (ATP) n = 8], incidence rate 4.7 per 100 patient years (95% CI 2.9-7.6). Eight inappropriate therapies occurred in 7 (8%) patients (ICD shock n = 4, ATP n = 4), incidence rate 1.1/100 patient years (95% CI 0.4-2.5). Three patients (3%) died following arrhythmic events, despite a functioning device. Other device complications were seen in 28 patients (31%), including lead-related complications (n = 15) and infection (n = 10). No clinical, device, or programming characteristics predicted time to inappropriate therapy or lead complication. CONCLUSION: In a large national cohort of paediatric HCM patients with an ICD, device and programming strategies varied widely. No particular strategy was associated with inappropriate therapies, missed/delayed therapies, or lead complications. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy Journal: J Thorac Cardiovasc Surg Date: 2011-12 Impact factor: 5.209
Authors: Juan Pablo Kaski; María Teresa Tomé Esteban; Martin Lowe; Simon Sporton; Philip Rees; John E Deanfield; William J McKenna; Perry M Elliott Journal: Heart Date: 2006-08-29 Impact factor: 5.994
Authors: Pieter A Vriesendorp; Arend F L Schinkel; Johan Van Cleemput; Rik Willems; Luc J L M Jordaens; Dominic A M J Theuns; Marjon A van Slegtenhorst; Thomy J de Ravel; Folkert J ten Cate; Michelle Michels Journal: Am Heart J Date: 2013-07-16 Impact factor: 4.749
Authors: Arend F L Schinkel; Pieter A Vriesendorp; Eric J G Sijbrands; Luc J L M Jordaens; Folkert J ten Cate; Michelle Michels Journal: Circ Heart Fail Date: 2012-07-20 Impact factor: 8.790
Authors: Peta M A Alexander; Alan W Nugent; Piers E F Daubeney; Katherine J Lee; Lynn A Sleeper; Tibor Schuster; Christian Turner; Andrew M Davis; Chris Semsarian; Steven D Colan; Terry Robertson; James Ramsay; Robert Justo; Gary F Sholler; Ingrid King; Robert G Weintraub Journal: Circulation Date: 2018-02-28 Impact factor: 29.690
Authors: Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins Journal: Eur Heart J Date: 2014-08-29 Impact factor: 29.983
Authors: Brynn E Dechert; David J Bradley; Gerald A Serwer; Macdonald Dick Ii; Martin J Lapage Journal: Pacing Clin Electrophysiol Date: 2016-05-27 Impact factor: 1.976
Authors: Anna N Kamp; Nicholas H Von Bergen; Charles A Henrikson; Majd Makhoul; Elizabeth V Saarel; Martin J Lapage; Mark W Russell; Margaret Strieper; Sunkyung Yu; Macdonald Dick; Sharlene M Day; David J Bradley Journal: Pediatr Cardiol Date: 2013-03-20 Impact factor: 1.655
Authors: Gabrielle Norrish; Aoife Cleary; Ella Field; Elena Cervi; Olga Boleti; Lidia Ziółkowska; Iacopo Olivotto; Diala Khraiche; Giuseppe Limongelli; Aris Anastasakis; Robert Weintraub; Elena Biagini; Luca Ragni; Terence Prendiville; Sophie Duignan; Karen McLeod; Maria Ilina; Adrian Fernandez; Chiara Marrone; Regina Bökenkamp; Anwar Baban; Peter Kubus; Piers E F Daubeney; Georgia Sarquella-Brugada; Sergi Cesar; Sabine Klaassen; Tiina H Ojala; Vinay Bhole; Constancio Medrano; Orhan Uzun; Elspeth Brown; Ferran Gran; Gianfranco Sinagra; Francisco J Castro; Graham Stuart; Hirokuni Yamazawa; Roberto Barriales-Villa; Luis Garcia-Guereta; Satish Adwani; Katie Linter; Tara Bharucha; Esther Gonzales-Lopez; Ana Siles; Torsten B Rasmussen; Margherita Calcagnino; Caroline B Jones; Hans De Wilde; Toru Kubo; Tiziana Felice; Anca Popoiu; Jens Mogensen; Sujeev Mathur; Fernando Centeno; Zdenka Reinhardt; Sylvie Schouvey; Perry M Elliott; Juan Pablo Kaski Journal: J Am Coll Cardiol Date: 2022-05-24 Impact factor: 27.203